Following this, we found that the levels of TNF-α and IL-10, a well-known biomarker for oral cancer [41,42,43], were significantly augmented in the control group; however, GSK343 treatment modulated these inflammatory players’ release in a concentration-dependent manner, counteracting inflammation. Here, IL10 is linked to lip and oral cavity carcinoma.